

27 June 2025

Treatment on Lung Cancer

1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) <5
- Amivantamab <5
- Atezolizumab Monotherapy <5
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel <5
- Atezolizumab subcutaneous <5
- Dabrafenib + Trametinib <5
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin <5
- Durvalumab <5
- Gemcitabine <5
- Nintedanib + Docetaxel <5
- Nivolumab <5
- Osimertinib 10
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) <5
- Paclitaxel <5
- Pembrolizumab Monotherapy 15
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) <5
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 9
- Pemetrexed + Platinum (Carboplatin/Cisplatin) <5
- RET Inhibitors (Pralsetinib, Selpercatinib) <5
- Sotorasib <5
- Tepotinib <5
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin 7
- Other active systemic anti-cancer therapy see below
- Palliative care only not available
- Amivantamab with carboplatin and pemetrexed <5
- Cemiplimab with platinum-based chemotherapy <5
- Gemcitabine Carboplatin <5
- Nivolumab Paclitaxel Carboplatin <5
- Paclitaxel Carboplatin 8

27 June 2025

Where numbers are low, we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

2. Does your trust participate in any Clinical trials for Non-Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.

Title acronym	Full Title	TOTAL recruitment at June 2025	Target
CONCORDE	A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non-small cell lung cancer	<5	<5
PACIFIC-9	A Phase III, double-blind, placebo-controlled, Randomized, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients with Locally Advanced (Stage III), Unresectable, Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive , Platinum-Based Concurrent Chemoradiation Therapy	<5	12